Safety and efficacy in the initiation of IDegLira for the outpatient with type 2 diabetes
Latest Information Update: 07 Jul 2022
At a glance
- Drugs Insulin degludec/liraglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
Most Recent Events
- 06 Jul 2022 According to UMIN, Date of closure to data entry is 5 July 2022, Date trial data considered complete and Date analysis concluded is 07 July 2022.
- 06 Jul 2022 Status changed from active, no longer recruiting to discontinued.
- 05 Jul 2020 Status changed from not yet recruiting to active, no longer recruiting.